MX360157B - Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr. - Google Patents

Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.

Info

Publication number
MX360157B
MX360157B MX2013005182A MX2013005182A MX360157B MX 360157 B MX360157 B MX 360157B MX 2013005182 A MX2013005182 A MX 2013005182A MX 2013005182 A MX2013005182 A MX 2013005182A MX 360157 B MX360157 B MX 360157B
Authority
MX
Mexico
Prior art keywords
diseases
egfr
treatment
agents
family members
Prior art date
Application number
MX2013005182A
Other languages
English (en)
Other versions
MX2013005182A (es
Inventor
Garcia-Echeverria Carlos
Maira Sauveur-Michel
Maria Brachmann Saskia
Fritsch Christine
René Schnell Christian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013005182A publication Critical patent/MX2013005182A/es
Publication of MX360157B publication Critical patent/MX360157B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

El uso de los compuestos de la fórmula (I): ( Ver Formula) en el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidérmico (EGFR) o de las enfermedades que hayan adquirido resistencia a los agentes que tengan como objetivo los miembros de la familia de los receptores del factor de crecimiento epidérmico (EGFR), el uso de estos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento de estas enfermedades, combinaciones de estos compuestos con moduladores de los receptores del factor de crecimiento epidérmico (EGFR) para dicho uso, los métodos para el tratamiento de estas enfermedades con tales compuestos, y las preparaciones farmacéuticas que comprenden estos compuestos para el tratamiento de dichas enfermedades, solos o en combinación, en especial con un modulador de los receptores del factor de crecimiento epidérmico (EGFR).
MX2013005182A 2010-11-08 2011-11-07 Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr. MX360157B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41111710P 2010-11-08 2010-11-08
PCT/EP2011/069522 WO2012062694A1 (en) 2010-11-08 2011-11-07 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Publications (2)

Publication Number Publication Date
MX2013005182A MX2013005182A (es) 2013-07-03
MX360157B true MX360157B (es) 2018-10-24

Family

ID=44947083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005182A MX360157B (es) 2010-11-08 2011-11-07 Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.

Country Status (12)

Country Link
US (4) US20130209461A1 (es)
EP (1) EP2637661B1 (es)
JP (4) JP2013542228A (es)
KR (1) KR101854484B1 (es)
CN (2) CN105412105A (es)
AU (1) AU2011328227B2 (es)
BR (1) BR112013009624A2 (es)
CA (1) CA2815492C (es)
MX (1) MX360157B (es)
RU (1) RU2589695C2 (es)
TR (1) TR201802943T4 (es)
WO (1) WO2012062694A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012322976B2 (en) * 2011-10-14 2016-05-12 Novartis Ag 2 - carboxamide cycloamino urea derivatives in combination with Hsp90 inhibitors for the treatment of proliferative diseases
EP2776026A1 (en) * 2011-11-02 2014-09-17 Novartis AG 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases
KR102112885B1 (ko) * 2012-08-07 2020-05-19 노파르티스 아게 B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물
IN2015DN00528A (es) * 2012-08-16 2015-06-26 Novartis Ag
MX2015014063A (es) * 2013-04-05 2015-12-11 Sanofi Sa Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
AU2014358773A1 (en) 2013-12-06 2016-06-02 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
BRPI0820722A2 (pt) 2007-12-20 2015-06-16 Novartis Ag Derivados de tiazol usados como inibidores de pi 3 cinases
NZ602675A (en) * 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

Also Published As

Publication number Publication date
JP2013542228A (ja) 2013-11-21
US20130209461A1 (en) 2013-08-15
CN105412105A (zh) 2016-03-23
JP2020114849A (ja) 2020-07-30
JP2016222686A (ja) 2016-12-28
AU2011328227A1 (en) 2013-04-18
AU2011328227B2 (en) 2015-04-09
MX2013005182A (es) 2013-07-03
BR112013009624A2 (pt) 2016-07-12
CA2815492C (en) 2019-04-09
KR20130143582A (ko) 2013-12-31
US20150250778A1 (en) 2015-09-10
TR201802943T4 (tr) 2018-03-21
EP2637661B1 (en) 2017-12-20
US20180325883A1 (en) 2018-11-15
EP2637661A1 (en) 2013-09-18
US20200022967A1 (en) 2020-01-23
RU2589695C2 (ru) 2016-07-10
KR101854484B1 (ko) 2018-05-03
RU2013126485A (ru) 2014-12-20
CN103200943A (zh) 2013-07-10
JP2019048822A (ja) 2019-03-28
WO2012062694A1 (en) 2012-05-18
CA2815492A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
AU2018260809A1 (en) Compounds and uses thereof for the modulation of hemoglobin
AU2018260808A1 (en) Compounds and uses thereof for the modulation of hemoglobin
PH12016500372A1 (en) Pharmaceutical composition containing pyrimidine compound as active ingredient
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
AU2011328009A8 (en) Compounds and methods for treating pain
EP2571357A4 (en) CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINAS MODULATION
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
MX368346B (es) Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
UA111579C2 (uk) ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
MX2013005182A (es) Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.
EA201370018A1 (ru) Составы рифаксимина и их применение
IL228600A0 (en) (Aralkylamino and heteroarylalkylamino alpha-converted) pyrimidinyl and 1,3,5-triazinyl benzaimidazoles, pharmaceutical compounds containing them and use of these compounds in the treatment of proliferative diseases
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
WO2014110353A9 (en) Notch ligand bound biocompatible substrates and their use in bone formation
TW201613578A (en) Pharmaceutical combinations
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
NZ601559A (en) Platelet-derived growth factor compositions and methods for the treatment of tendinopathies

Legal Events

Date Code Title Description
FG Grant or registration